Novel diversity-oriented synthesis-derived respiratory syncytial virus inhibitors identified via a high throughput replicon-based screen.

Antiviral Res
Authors
Abstract

Respiratory syncytial virus (RSV) infections affect millions of children and adults every year. Despite the significant disease burden, there are currently no safe and effective vaccines or therapeutics. We employed a replicon-based high throughput screen combined with live-virus triaging assays to identify three novel diversity-oriented synthesis-derived scaffolds with activity against RSV. One of these small molecules is shown to target the RSV polymerase (L protein) to inhibit viral replication and transcription; the mechanisms of action of the other small molecules are currently unknown. The compounds described herein may provide attractive inhibitors for lead optimization campaigns.

Year of Publication
2016
Journal
Antiviral Res
Volume
131
Pages
19-25
Date Published
2016 Jul
ISSN
1872-9096
URL
DOI
10.1016/j.antiviral.2016.03.015
PubMed ID
27059228
PubMed Central ID
PMC4937797
Links
Grant list
R01 AI113321 / AI / NIAID NIH HHS / United States